Introduction {#Sec1}
============

Autism is a neurodevelopmental disorder defined by impairments in social interaction, deficits in verbal and nonverbal communication, and the display of stereotyped and repetitive behaviors. Comorbid symptoms include intellectual disability, seizures, anxiety, aggression, and sleep disorders. Typical autism is at the extreme end of the autism spectrum, which also includes Asperger\'s syndrome, childhood disintegrative disorder and a set of disorders referred to as pervasive developmental disorder (PDD) not otherwise specified. The prevalence of autism spectrum disorder (ASD) is estimated to range between ∼25 and ∼110 in every 10,000, placing a substantial socioeconomic burden on families and society (Baird et al. [@CR8]; Kogan et al. [@CR58]). Although pharmacotherapy can manage ASD comorbidities, it does not address the core deficits. Current treatments are focusing on educational and behavioral interventions aimed at ameliorating maladaptive behaviors and promoting social interactions (Myers and Johnson [@CR76]).

A prerequisite for the development of pharmacological agents targeting the core symptoms of ASD is a deeper understanding of the underlying pathophysiology. ASD has a strong genetic component and a small fraction of ASD cases is caused by defined genetic aberrations. Several mouse models of these syndromic forms of autism have provided insight into dysregulated pathways. The advent of somatic cell reprogramming now enables the study of ASD neurobiology using patient-derived cells. Ectopic expression of the four transcription factors Klf-4, Oct4, Sox2, and c-Myc induces reprogramming of somatic human cells to a pluripotent state (Takahashi et al. [@CR110]; Takahashi and Yamanaka [@CR109]). These human induced pluripotent stem cells (hiPSCs) retain the genetic composition of the cells they have been derived from (with the exception of stably integrated transgenes in the case of retro- or lentiviral approaches) and, owing to their pluripotent state, can be differentiated into cell types of all three germ layers. hiPSCs have characteristics similar to those of human embryonic stem cells (hESCs), derived from the inner cell mass of the embryonic blastocyst, and together hiPSC and hESCs are referred to as human pluripotent stem cells (hPSCs) in this review. Although reprogramming was initially established using dermal fibroblasts and using integrating viral vectors, recent advances allow derivation of hiPSCs from cell types accessible by less invasive methods, such as from keratinocytes (Aasen et al. [@CR1]), peripheral blood T lymphocytes (Brown et al. [@CR15]; Seki et al. [@CR96]), and exfoliated renal epithelial cells found in urine samples (Zhou et al. [@CR120], [@CR121]). In combination with efficient transgene-free reprogramming (Fusaki et al. [@CR38]), these improvements facilitate the generation of hiPSCs from patients enrolled in clinical trials or studies.

A major limitation of hiPSC-based disease models is the fact that they necessitate the use of hiPSC lines generated from unaffected individuals as controls. Differences in genetic makeup are likely to contribute to interclonal variability between lines, further adding to differences in their properties caused by the reprogramming procedure itself (Hu et al. [@CR50]). While in practice, these issues are addressed by generating multiple hiPSC lines from multiple patients and control individuals, the effect size of the phenotypes to be observed is usually unknown, making it impossible to estimate the number of cell lines required a priori. These barriers inherent in hiPSC-based disease modeling can be circumvented by targeted genetic manipulation of hPSCs. Sequence-specific designed zinc finger nucleases (ZFNs) or transcription activator-like effector nucleases (TALENs) can be used to generate a double strand break at a specific locus in the genome of hPSCs, allowing gene targeting via homology-directed repair or non-homologous end joining (Ding et al. [@CR28]; Lombardo et al. [@CR67]). ZFNs and TALENs are now readily available (Kim et al. [@CR55]; Xiao et al. [@CR116]), enabling the disruption or mutation of virtually any gene. Recently developed advanced sequence-specific nuclease systems show improved targeting efficiency, making deletion even of large genomic segments possible, and thus open the door to model diseases caused by copy number variations (CNVs) (Cong et al. [@CR24]; Ding et al. [@CR29]).

In this review, we provide a summary of the potential application of hPSCs for the generation of cellular models of ASD. We illustrate how insights from human genetic and transcriptome pathway studies as well as from mouse models inform the design of relevant hPSC models and discuss recent advances towards the generation of hPSC-derived neuronal populations that may enable modeling of human circuitry dysfunction in ASD.

Human genetics, mouse models, and pathway analyses: guiding the selection of appropriate hPSC models {#Sec2}
====================================================================================================

Human genetics {#Sec3}
--------------

ASD is highly heritable, with concordance rates in monozygotic twins estimated to be as high as 90 % (Bailey et al. [@CR7]; Steffenburg et al. [@CR107]). Even though the causes of ASD are largely unknown, heritability provides a strong rationale for modeling ASD using genetically modified hPSCs and patient-derived hiPSCs, since neuronal populations derived from them will carry the causative genetic aberrations, which may lead to relevant neuronal dysfunction observable in vitro. Despite high heritability, the upper limit of the fraction of patients that harbor known genetic mutations likely causative for ASD is currently estimated at ∼30--45 % (Schaaf and Zoghbi [@CR94]; Stein et al. [@CR108]), indicating that the majority of genetic defects remain to be identified in idiopathic cases. Indeed, recent results from CNV (Gilman et al. [@CR41]; Levy et al. [@CR63]; Sanders et al. [@CR92]) and exome sequencing (Lim et al. [@CR65]; Michaelson et al. [@CR74]; Yu et al. [@CR118]) studies in large autism cohorts point to the involvement of hundreds of genes conferring ASD risk when mutated, disrupted, or duplicated. Overall, these genetic studies support a largely polygenic susceptibility model in which a minority of patients carries one of a few highly penetrant genetic aberrations, while the majority of patients harbor a small subset of hundreds of genetic aberrations that individually convey subthreshold risk (Neale et al. [@CR77]). Models of genetically defined, syndromic forms of autism have provided critical insights into disease-causing mechanisms. They support the notion that despite the genetic heterogeneity, pathophysiological trajectories of ASD converge onto a limited number of affected pathways. Future research will address whether these emerging concepts will extend to idiopathic cases of ASD.

Many of these high-risk alleles are recurrent CNVs that affect large arrays of genes, while others are point mutations or small insertions and deletions (indels) which, although individually unique, collectively converge on a limited set of genes (Kelleher and Bear [@CR53]). Intriguingly, most of these genes fall into two broad functional classes, namely, genes predominantly involved in regulating synapse structure and function (e.g., SHANK3, CNTNAP2, NRXN1, NLGN3/4X) and those involved in transcriptional and/or translational control (e.g., TSC1/2, MECP2, NF1, PTEN) (see review by Bourgeron et al. in this issue). The large numbers of genes affected in CNVs (which are readily detected using genome-wide microarrays and thus have been found more frequently than smaller indels or mutations, whose detection requires some form of targeted sequencing) present a challenge for the identification of causal genes. Network-based approaches for the analysis of genetic associations, using as input data genes affected by CNVs from ASD patients, may help address this challenge. Figure [1](#Fig1){ref-type="fig"} shows a roadmap illustrating how insights from network-based analyses of genetic and transcriptomic data from ASD patients can inform the design of relevant ASD cellular models.Fig. 1A roadmap towards ASD modeling in hPSCs. Genomic analysis from ASD patients identifies those who harbor genetic defects that might be causal and hiPSCs from these patients can be generated from biopsy material. Insight into shared pathophysiological trajectories comes from pathway analyses of genetic aberrations, as well as from network-based analyses of gene expression in postmortem brains of ASD patients. Guided by the identification of pathways commonly dysregulated in larger subsets of patients, this knowledge informs the selection of genes to be targeted to create additional ASD models. If present in the patient cohort, these can be generated by somatic cell reprogramming. Alternatively, additional genotypes can be obtained from normal hPSCs via targeted genetic manipulation using genome editing. Control hPSCs may also be generated from patient hPSCs by reverting the causative genetic aberration using genome editing

In one such network-based approach, termed NETBAG (Gilman et al. [@CR41]), a large set of gene descriptors was first used to construct a background network of genes that are clustered based on their likelihood of contributing to a shared phenotype. When 433 candidate genes affected by 47 de novo CNVs from a large autism patient cohort were then mapped onto the network and interrogated for their capacity to support the preformed connections, several single genes within CNVs emerged as significantly associated (Gilman et al. [@CR41]). HPSC lines with gene disruptions in these candidate genes, or in genes directly linked within the same cluster, will expand the range of human cellular ASD models and will enable direct probing of implicated pathways. In addition, such models will subsume genetic aberrations shared by several patients. Recent advances in genome editing technology now make it possible to construct such synthetic hPSC-based models, including those for which patient cells are not available for reprogramming (Fig. [1](#Fig1){ref-type="fig"}). Common molecular dysfunction observed in these models will also aid in patient stratification.

Despite the paucity of knowledge of "culprit" genes in CNVs, these disorders have advanced our understanding of autism pathophysiology. CNVs where deletions and reciprocal duplications cause largely overlapping clinical phenotypes, and those where the reciprocal change leads to opposing phenotypes, have been particularly instructive. For example, a CNV on 16p11.2 deleting ∼600 kb and encompassing ∼25 known coding genes is associated with autism, while duplication of the same region is associated with autism and schizophrenia (McCarthy et al. [@CR71]). 16p11.2 deletions and duplications are also linked to macrocephaly and microcephaly, respectively (McCarthy et al. [@CR71]). In contrast, deletion of a ∼1.5-Mb chromosomal segment on 7q11.23 containing ∼28 genes causes Williams syndrome (Merla et al. [@CR72]). Individuals affected by this disorder have generally good verbal skills relative to their intelligence quotient and, strikingly, tend to be exceedingly sociable, approach strangers readily and hyperfocus on the eyes of others (Mervis and John [@CR73]). In contrast, duplication of this region is associated with autism, mental retardation, language impairment, and epilepsy (Mervis and John [@CR73]; Sanders et al. [@CR92]). Lastly, loss of a ∼5-Mb region on 15q11-13, harboring 10--15 coding genes, on the maternal chromosome causes Angelman syndrome (Pembrey et al. [@CR83]), characterized by developmental delay, speech impairment, ataxia, and a unique combination of behavioral phenotypes that include a generally happy disposition, frequent smiling and laughing, and excitability (Williams et al. [@CR115]). In contrast, individuals with duplications or triplications encompassing this region are autistic, with penetrance of ASD phenotypes correlating with CNV dosage (Hogart et al. [@CR49]). Thus, syndromes related to one another by reciprocal CNVs illustrate that opposing gene dosage can lead to either converging or opposing clinical phenotypes. The example of the 16p11.2 CNV suggests that the autism phenotype may not be linked to its specific copy number (and, consequently, to gene dosage). Analyses of CNVs in rodents and humans have shown that, instead, it may be the structural change in the genome caused by the CNV that contributes to the phenotype. Support for this hypothesis comes from rodent studies of CNV-dependent dosage sensitivity of gene expression. Here, an only modest correlation between copy number and gene dosage was observed in general, with particularly low correlation in the brain (Henrichsen et al. [@CR46],[@CR47]; Reymond et al. [@CR89]). These observations have major implications for modeling functional consequences of CNVs in mouse models (see below).

Nevertheless, hiPSC models of these syndromes may help understand how and where on the pathophysiological trajectory these reciprocal CNV syndromes converge or diverge. Although knowledge of the critical genes in these CNVs is still limited, experiments in zebrafish have linked the head size phenotype in 16p11.2 CNVs to dysregulation of the neural progenitor cell (NPC) proliferation gene *KCTD13*, which codes for a protein that interacts with the proliferating cell nuclear antigen (Golzio et al. [@CR44]). The finding that a subset of Angelman patients harbor point mutations in *UBE3A* within the 15q11-13CNV strongly suggests that dysfunction of this gene, coding for an E3 ubiquitin ligase, is primarily responsible for the phenotype (Kishino et al. [@CR57]). Targeted genetic manipulation of these candidate genes in hPSCs will help identify the molecular underpinnings of ASD and may ultimately serve as cellular models (Fig. [1](#Fig1){ref-type="fig"}).

Further advances, alongside reductions in the costs associated with deep sequencing, will make whole genome sequencing of large patient cohorts feasible in the near future. These studies will undoubtedly reveal additional small risk-conferring genetic defects (indels and point mutations) outside of the coding regions of known genes, particularly in promoter and enhancer regions, where variation in human populations is higher than in coding regions, and within long non-coding ribonucleic acids (RNAs), which have recently come into focus as important players in neurogenesis and neuropsychiatric disorders (Lin et al. [@CR66]). These advances will likely expand the set of informative genotypes, which can be exploited to model ASD with human hPSCs.

Insights from transcriptome analyses in human brain postmortem brain {#Sec4}
--------------------------------------------------------------------

Volumetric magnetic resonance imaging (MRI) studies, combined with structural analyses of postmortem brains of ASD patients, have identified associated neuroanatomical and cellular aberrations. Overall, these findings point to increased brain growth beginning in the first postnatal year, persisting at least into early childhood (Courchesne et al. [@CR26]). More detailed analyses have revealed changes in neuronal size, number, and density, as well as defects in neuronal organization in frontal and temporal cortex, anterior cingulate, amygdala, and cerebellum (Amaral et al. [@CR2]; Schumann and Nordahl [@CR95]). Although these alterations are likely due to defects in regulation of neuronal differentiation, proliferation, and migration, their molecular underpinnings remain elusive. Transcriptome analyses of these brain regions in large cohorts of ASD patients may help identify commonly dysregulated pathways converging from the heterogeneous genetic background of the disorder (Fig. [1](#Fig1){ref-type="fig"}). Such studies, however, have only recently begun to emerge (Chow et al. [@CR22]; Voineagu et al. [@CR114]).

In a seminal paper, Geschwind and colleagues analyzed the transcriptomes of frontal and temporal cortex and cerebellum from 19 postmortem brains from idiopathic cases of ASD and from 17 control individuals (Voineagu et al. [@CR114]). An analysis approach based on identification of gene coexpression networks revealed that the most significantly ASD-correlated module of functionally related genes was enriched for genes involved in synaptic function, as well as for known autism susceptibility genes. Thus, in addition to confirming involvement of synaptic dysfunction in ASD, these findings strongly suggest that transcriptomic approaches can identify molecular commonalities in ASD brains, and we can now address whether hiPSC-derived neurons can identify these molecular signatures. The dominant module was anchored by *A2BP1*, the gene coding for the neuron-selective splicing factor RBFOX1, thus implicating splicing dysregulation in ASD (Fogel et al. [@CR37]). Since *A2BP1* itself had previously been identified as an autism susceptibility gene in humans (Martin et al. [@CR70]), these results provide a strong rationale for creating hPSC-based ASD models with defects in this gene. Intriguingly, the study also showed that differences in gene expression patterns between frontal and temporal cortex were attenuated in ASD brains, suggesting defects in cortical specification, patterning, and/or organization (Voineagu et al. [@CR114]). Thus, similar to network-based analyses of de novo CNVs in ASD patients, postmortem transcriptome studies pinpoint pathways commonly dysregulated in ASD (Fig. [1](#Fig1){ref-type="fig"}). Transcriptome profiles will also help validate and benchmark hPSC-based models---either obtained by cellular reprogramming of patient-derived cells or generated by genome editing in normal hPSCs---of critical genes within these pathways and will be crucial to test the relevance of pathways implicated in ASD pathophysiology.

Mouse models {#Sec5}
------------

Mouse models of genetically defined, syndromic forms of ASD phenocopy core autism deficits and have provided critical insight into pathophysiological mechanisms. In mouse models of fragile X syndrome, Rett syndrome and tuberous sclerosis complex, reversal of autism phenotypes by pharmacological and/or genetic intervention has been achieved after brain development. These studies suggest that pharmacological intervention may be a viable disease-modifying approach in both children and adults. However, at least in part due to differences in trajectories of brain development and anatomy, translation from mouse models to the human condition has been particularly difficult for central nervous system (CNS) diseases (Dragunow [@CR31]). Human cellular models that recapitulate human-specific aspects of brain development and anatomy, particularly cortical specification and organization, can help to bridge this gap in translational ASD research.

Differences in the genomic make-up and transcriptional regulation between mouse and human pose a challenge to model human genetic variants, particularly CNVs, in mouse. When genomic regions affected by CNVs are not syntenic between mouse and human, the mouse chromosomal region corresponding to its human counterpart will not contain the same set of genes. Since CNVs have been shown to affect expression patterns of genes distal to the CNV breakpoints (Reymond et al. [@CR89]), this caveat also applies to chromosomal regions surrounding the CNV. Moreover, human-specific transcriptional processes, such as alternative promoter usage and alternative splicing, are also not replicated in a heterologous system. Thus, hPSC-based disease models of ASD caused by CNVs may be more likely to recapitulate human disease etiology.

The fact that some ASD patients carry two genetic defects suggests that these may act in concert, supporting a multi-hit model for ASD. For example, ASD patients with a deletion at 16p12.1 are more likely to harbor an additional CNV than would be expected by chance (Girirajan et al. [@CR42]). In addition, three patients found to carry mutations in the synaptic scaffolding protein SHANK2 additionally harbored CNVs in 15q11-13 (Leblond et al. [@CR61]), a region previously implicated in ASD (see above). Modeling these two-hit genotypes in mouse would require construction of double-knockout mice; a more direct path would therefore be the use of patient-derived hiPSCs for modeling of ASD caused by multiple genetic aberrations.

In the past, the vast majority of genetically defined ASD mouse models have been built to genocopy mutations found in the patient population. Our growing understanding of the common molecular pathways dysregulated in different forms of ASD has now begun to enable the design of novel mouse models (or the use of pre-existing models that have not previously been considered as ASD models) that may subsume aspects of ASD pathology arising through diverse etiologies. A first glimpse into this new direction in ASD research has been provided by the finding that RBFOX1 is downregulated in brains of idiopathic ASD patients, as described above (Voineagu et al. [@CR114]). Excitingly, a CNS-specific *Rbfox1* knockout mouse has been shown to have an increase in neuronal excitability and susceptibility to spontaneous seizures, a common ASD comorbidity (Gehman et al. [@CR40]). It will be interesting to see whether this mouse also displays core behavioral phenotypes of autism.

One of the central hypotheses for molecular mechanisms shared among different forms of ASDs is aberrant regulation of translation causing increased protein synthesis (Kelleher and Bear [@CR53]). For example, a positron emission spectroscopy imaging study of children with pervasive developmental disorder showed a positive correlation of autism index scores with protein synthesis rates in language brain regions (Shandal et al. [@CR97]). In addition, translation is the final common mechanism regulated by the fragile X mental retardation protein (FMRP) and mTOR pathways, both strongly linked to autism (see below). Transgenic mice mildly overexpressing eIF4E, the rate-limiting factor in the assembly of the translation initiation complex, show autistic-like behaviors, increased miniature excitatory postsynaptic current (mEPSC) frequency and amplitude and enhanced hippocampal metabotropic glutamate receptor (mGluR)-mediated long-term depression (LTD) (Santini et al. [@CR93]). Similarly, mice null for one of the three eIF4E-binding proteins (*Eif4ebp2* knockout), which sequester eIF4E, display autism-related deficits and an increased ratio of excitatory to inhibitory synaptic inputs (Gkogkas et al. [@CR43]). Strikingly, among 24 autism-relevant proteins examined in both models, only neuroligins (*Nlgn1-4*) showed enhanced translation, indicating strong selectivity in the genes affected by the loss of eIF4E-dependent translational control (Gkogkas et al. [@CR43]). The ASD-like phenotypes could be reversed by *Nlgn1* knockdown and by intracerebroventricular infusion of the small-molecule inhibitor of cap-dependent translation, 4-EGI (Santini et al. [@CR93]). Translation dysfunction thus links upstream signaling defects to downstream synaptic dysfunction, strongly implicating translation hyperfunction as a defect common in both syndromic and idiopathic ASD. The advent of genome editing now makes it possible to similarly create hPSCs with translation dysregulation, paving the road towards human cellular models of idiopathic ASD (Fig. [1](#Fig1){ref-type="fig"}).

Existing hiPSC models of ASD: insights from genetically defined cases {#Sec6}
=====================================================================

Identification of phenotypes in hiPSC-based models of ASD has been achieved in four syndromic forms of ASD with known single gene defects: Rett syndrome (RTT), Phelan-McDermid Syndrome (PMDS), Timothy syndrome (TS), and fragile X syndrome (FXS). These studies have paved the way for the use of hiPSC-derived neuronal populations as cellular models of ASD. Electrophysiological analyses of hiPSC-derived neurons have demonstrated fundamental neuronal firing properties and spontaneous inhibitory and excitatory currents, demonstrating synaptic connectivity. Although the neurons of the middle to upper cortical layers of the human cortex provide the intracortical circuitry that is among those thought to be perturbed in ASD, these types of neurons are not generated in basic hPSC differentiation protocols. Nevertheless, since more recent differentiation protocols have begun to address neuronal region specificity, these hPSC lines can now be used for more detailed analyses of neuronal function at the network and circuit levels (see below).

Rett syndrome {#Sec7}
-------------

RTT is a severe X-linked neurodevelopmental disorder that occurs in approximately 1 in 10,000 female births and confers a highly increased risk of developing autism-like behaviors and seizures (Chahrour and Zoghbi [@CR17]). RTT was the first PDD for which a genetic cause could be identified (Amir et al. [@CR3]) and, more than 10 years later, the first PDD for which hiPSC-based models were established (Marchetto et al. [@CR69]). Thus, animal and cellular models of RTT have become prototypical for understanding the molecular pathophysiology of RTT and have nurtured the hope that insights gained from them may extend to other ASDs. Typical RTT is caused by defects in the gene encoding the transcriptional regulator, methyl CpG binding protein 2 (MECP2), involved in transcriptional regulation via alteration of chromatin structure (Baker et al. [@CR9]). Clinical manifestations of RTT include severe intellectual disability, loss of language, stereotypic hand wringing, and motor abnormalities.

Even prior to the identification of *MECP2* as the gene affected in RTT, morphological alterations to neuronal structure had been observed in human postmortem tissue, notably small neuronal size and reduced dendritic arbors in specific cortical areas and layers (Armstrong et al. [@CR4], [@CR5]). Strikingly, these abnormalities were subsequently found in mice mutant for *Mecp2* (Chen et al. [@CR20]; Kishi and Macklis [@CR56]). Although an in vitro approach using cultured dissociated neurons from these mice did not find any effects on dendritic branching or complexity (Chao et al. [@CR19]), hiPSC-derived neurons from RTT patients and hESC-derived *MECP2* hemizygous neurons, created by genome editing, also have significantly reduced cell soma size and dendritic branching (Cheung et al. [@CR21]; Marchetto et al. [@CR69]). *MECP2* mutant neurons showed a global reduction in transcriptional output (Yazdani et al. [@CR117]), with levels of actively transcribed genes being particularly affected (Li et al. [@CR64]). Synaptic deficits have been observed in models spanning from human RTT hiPSC- (Marchetto et al. [@CR69]) and hESC-derived neurons (Li et al. [@CR64]), iPSC-derived neurons from mice mutant for *Mecp2* and mouse mutant neuronal cultures (Chao et al. [@CR19]), in vitro acute brain slices from mutant mice (Dani et al. [@CR27]), and even, at least to a limited extent, to in vivo data from mutant mice (Chao et al. [@CR19]). In the aggregate, these data suggest that, in the absence of MECP2, neurons fail to maintain gene expression at levels critical for neuron-specific functions, including activity-dependent transcription (Li et al. [@CR64]).

Electrophysiological analysis of spontaneous miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs) can impart information on the number and type of synaptic connections in a neural network. HiPSC-derived neurons from patients with RTT show reduced frequency and amplitude of mEPSCs and, to a lesser extent, mIPSCs (Marchetto et al. [@CR69]). Combined with data demonstrating fewer puncta of a presynaptic marker of excitatory synapses, the lower frequency indicates that RTT neurons produce fewer synapses. The reduction in amplitude suggests a concomitant reduction in postsynaptic receptors. While these abnormalities have been described in various rodent models of ASD (Chao et al. [@CR19]; Peca et al. [@CR82]), considerable care needs to be taken in their interpretation, given that in vivo developmental and in vitro cell line variability can be high. Moreover, the hiPSC-derived RTT neurons were a mixture of glutamatergic and GABAergic neurons with unknown regional identity. A detailed study of iPSC-derived neurons from *Mecp2* mutant mice found reductions in mEPSC frequency in female heterozygotes, but no change in mEPSC amplitude or any abnormality in neurons from male heterozygotes (which have no MECP2 protein) (Farra et al. [@CR34]). However, these studies did find consistent abnormalities in action potential amplitude and rise time, sodium currents, and the number of action potentials generated by a given stimulus (Farra et al. [@CR34]). Although these detailed electrophysiological analyses have yet to be performed in hPSC-based models of RTT, analyses using multielectrode arrays (MEAs) unveiled reduced spontaneous action potential rates in the hESC-based RTT model (Li et al. [@CR64]). Moreover, hiPSC-derived RTT neurons showed a reduced frequency of calcium transients under conditions selective for synaptically connected neurons (Marchetto et al. [@CR69]). In the aggregate, these data point to alterations in network activity and connectivity in RTT neurons.

A candidate approach, informed by the knowledge of reduced excitatory drive and synaptic connections, led to the use of insulin-like growth factor 1 (IGF-1) in mouse models of RTT. Here, administration of IGF-1 to mice mutant for *Mecp2* resulted in a partial reversal of many aspects of the phenotype, including the synaptic abnormalities (Tropea et al. [@CR111]). Excitingly, IGF-1 applied to hiPSC-derived RTT neurons rescued the reduction in excitatory synapses (Marchetto et al. [@CR69]). Similarly, the reduction in protein synthesis seen in hESC-derived *MECP2* mutant neurons, created by genome editing, could be rescued by application of brain-derived neurotrophic factor (BDNF) or IGF-1 (Li et al. [@CR64]). These observations provide a first glimpse of the possibility of using hPSC-derived RTT neurons as an ASD model for drug screening.

Phelan-McDermid Syndrome {#Sec8}
------------------------

Phelan-McDermid Syndrome (PMDS) is a neurodevelopmental disorder caused by deletion of of the SHANK3 gene on the terminal end of chromosome 22 (also known as 22q13 deletion syndrome). It causes a wide range of symptoms including seizures, intellectual disability and sleep disorders, as well as being strongly associated with ASD (Phelan and McDermid [@CR87]). Recently, hiPSC-derived neurons have been generated from PMDS patients and were found to have significant deficits in excitatory synaptic transmission. Not only were these deficits rescuable by expression of SHANK3 itself, but they were also corrected by pharmacological treatment with IGF-1 (Shcheglovitov et al. [@CR98]). These results add weight to the concept that synaptic abnormalities may be treatable by pharmacotherapy, and indeed that where diverse genetic defects converge on similar synaptic dysfunction there may be commonalities in treatment options.

Timothy syndrome {#Sec9}
----------------

Timothy syndrome (TS) is an extremely rare autosomal dominant multisystem disorder caused by mutations in *CACNA1C*, coding for the alpha-1 (voltage sensor and pore-forming) subunit of the L-type voltage-gated calcium channel Ca~V~1.2 (Splawski et al. [@CR104], [@CR105]). A member of the long QT family of syndromes, TS causes prolongation of the cardiac QT interval in affected individuals. Patients with classic (type 1) TS harbor a recurrent de novo missense mutation (Gly→Arg) at position 406 in exon 8A. Approximately 25 patients with classic TS have been described, while two patients with a more severe variant of TS (atypical or type 2 TS) have a Gly→Arg mutation in the more highly expressed alternative exon 8 (Splawski et al. [@CR106]). As CACNA1C is expressed in multiple tissues, mutation causes dysfunction in multiple organs, including syndactyly (in 100 % of type 1 cases), congenital heart disease (61 %), cardiac arrhythmia (84 %), immune deficiency (57 %), and autism (75 %). TS type 2 is characterized by the presence of extreme prolongation of the QT but absence of syndactyly. TS patients die at an average of 2.5 years, and the leading cause of death is ventricular tachycardia. Thus, as is common with syndromic forms of autism, morbidity caused by autistic behaviors is a relatively minor aspect within a large spectrum of severe clinical manifestations (Splawski et al. [@CR106]).

Dolmetsch and colleagues generated cortical-enriched neuronal populations differentiated from several hiPSC lines derived from two type-1 TS patients and showed that mutant neurons exhibit action potentials wider than those of control cells, in agreement with a loss of Ca~V~1.2 channel inactivation caused by the mutation (Pasca et al. [@CR80]). Calcium imaging in cortical progenitors and in synapsin-positive mature neurons revealed an increase in the sustained intracellular calcium rise following membrane depolarization, strongly suggesting that TS NPCs and neurons have deficiencies in calcium signaling, with concomitant changes in activity-dependent gene expression. Remarkably, TS neuronal cultures contained more cells expressing tyrosine hydroxylase and produced more norepinephrine and dopamine, a phenotype also observed in the valproic acid model of ASD (D\'Souza et al. [@CR32]). Unexpectedly, of those neurons in the culture that expressed lower layer cortical markers, TS neurons also contained fewer cells expressing SATB2, critical for formation of corpus callosum projection neurons. This observation was confirmed in a transgenic mouse model expressing the mutant channel under the forebrain-specific *FOXG1* promoter (Pasca et al. [@CR80]). Thus, these results indicate that neuronal specification deficits caused by TS mutations can be recapitulated in both hiPSC-derived neurons and mouse models. The study also underscores the fact that differentiation of hiPSC-derived neurons of appropriate subtypes is critical to reveal alterations in neuronal specification, as such changes may contribute to neural circuitry dysfunction in ASD patients.

A mouse model of type 2 TS showed robust behavioral phenotypes reflecting the three core traits of autism, including restricted, repetitive, and perseverative behaviors, reduced socialization with other animals, and altered ultrasonic vocalization (Bader et al. [@CR6]). Although analyses of alterations in neuron morphology and function or brain circuitry that may underlie these behaviors were not reported in this study, a similar mouse model was recently constructed and characterized by Dolmetsch and colleagues (Krey et al. [@CR59]). Ca~V~1.2 couples changes in membrane potential to dendritic arborization, possibly by recruiting small GTP-binding protein family members, which in turn regulate signaling controlling arborization. Frontal cortex layer 2/3 pyramidal neurons from TS mice showed a decrease in total basal dendritic length and the number of dendritic branches by postnatal day 14, indicating a net reduction in basal dendritic complexity in an early postnatal phase. Importantly, these effects on activity-dependent dendritic refinement were also observed in vitro, using both primary rat cortical neurons and several hiPSC neuronal lines from the two type-1 TS patients. Detailed analyses revealed that mutant Ca~V~1.2 channels are deficient in recruiting sufficient levels of the small GTP-binding protein Gem, thus causing excessive activation of RhoA and activity-dependent dendritic retraction independent of calcium signaling (Krey et al. [@CR59]). These insights highlight that hiPSC modeling of ASD requires assays tailored to the known function of the affected gene to unravel pathophysiological mechanisms. The study also illustrates the value of a complementary approach that includes evidence from rodent and human cellular models and in vivo rodent data.

Fragile X syndrome {#Sec10}
------------------

Fragile X syndrome (FXS) is an X-linked dominant disorder and the most common form of inherited intellectual disability, affecting ∼1 in 4,000 newborns (Coffee et al. [@CR23]). Clinically, FXS is characterized by mild to severe cognitive deficits and behavioral abnormalities that include hyperactivity and autism-like behaviors (Gallagher and Hallahan [@CR39]). The syndrome is caused by the absence of expression of the fragile X mental retardation 1 (*FMR1*) gene, coding for the RNA binding protein FMRP. Typically, loss of FMRP in FXS is caused by abnormal CGG triplet repeat expansion in the 5′ untranslated region (5′ UTR) of the gene, leading to developmentally controlled CpG methylation in the promoter and 5′ UTR region and thus resulting in gene silencing (Feng et al. [@CR36]). Repeat numbers \>200 lead to complete silencing in neurons and cause FXS, while repeat expansions in the premutation range (55--200 repeats) are associated with upregulation of FMR1 expression and cause the late onset neurodegenerative disease, fragile X associated tremor ataxia syndrome, probably via a toxic gain of function of the CGG-rich RNA transcript (Gallagher and Hallahan [@CR39]).

Although a mouse model carrying ∼230 repeats did not recapitulate the abnormal methylation of the promoter and 5′ UTR methylation seen in humans (Brouwer et al. [@CR14]), *Fmr1* knockout mice display many features of FXS, including autistic behaviors (Consortium TD-BFX [@CR25]). FMRP, a suppressor of messenger RNA translation, is required for activity-dependent regulation of synaptic protein synthesis, which is stimulated by activation of group 1 mGluRs, including mGluR5. Since many of the long-term consequences of mGluR5-mediated signaling, including LTD, are dependent on protein translation, it has been hypothesized that mGluR5 inhibition could counteract neuronal dysfunction in FXS (Bear et al. [@CR11]). Indeed, strong support for the "mGluR5 hypothesis for FXS" theory comes from several recent studies in which pharmacological or genetic intervention aimed at reducing mGluR5-dependent signaling prevented and/or reverted FXS phenotypes (Dolen et al. [@CR30]; Michalon et al. [@CR75]; Silverman et al. [@CR103]).

Human ESCs derived from FXS-affected blastocyst-stage embryos express FMRP and gene silencing via promoter methylation occurs only upon differentiation (Eiges et al. [@CR33]). In contrast, hiPSCs derived from fibroblasts of affected patients showed deoxyribonucleic acid (DNA) methylation and transcriptional silencing even in the pluripotent stage, indicating that somatic reprogramming did not erase these chromatin marks (Urbach et al. [@CR112]). Thus, although these hiPSCs do not recapitulate developmentally regulated FMR1 silencing, they may nevertheless represent a useful model system for screening of compounds capable of reactivating the gene (Bar-Nur et al. [@CR10]). Differentiation of hiPSCs towards neurons showed reduced neurite numbers and neurite lengths (Sheridan et al. [@CR99]), phenotypes that resemble those seen in the *Fmr1* knockout mouse (Braun and Segal [@CR12]; Luo et al. [@CR68]) and in human FXS postmortem tissue (Castren et al. [@CR16]). In the future, it will be important to address whether FXS hiPSC-derived neurons display exaggerated mGluR5 signaling and defects in LTD and, if so, whether these phenotypes can be reverted with mGluR5 inhibitors.

ASD modeling in a dish: towards neuronal circuits {#Sec11}
=================================================

An outstanding question is whether hPSC-derived neurons will be useful for identifying new therapeutic targets and for developing disease-relevant phenotypes for high throughput screens. The ability to study diseases of the cerebral cortex in vitro and to observe disease-relevant phenotypes will depend on the ability to produce neuronal cultures of defined cellular composition.

Efficient neural specification using defined morphogens {#Sec12}
-------------------------------------------------------

Major advances in the establishment of human neuronal differentiation protocols now nurture the hope that we may be able to build specific cellular networks from hPSCs in the near future. A number of groups have established robust morphogen-based protocols to drive mouse embryonic stem cells into neurons of specific regional and functional identity, including dopaminergic, striatal, motor, and cortical neurons (Hansen et al. [@CR45]). These morphogens, together with signaling through specific cell-to-cell contacts, dictate neuronal specification by inducing signal transduction cascades (Hansen et al. [@CR45]). In contrast, early procedures to produce human neural cells from hPSCs either relied on coculture with stromal feeder cells, which induce neural conversion through the action of undefined factors, or depended on the generation of three-dimensional heterogeneous cellular aggregates (so-called embryoid bodies) from which neural precursor cells were subsequently isolated. Both approaches yielded neuronal cultures of variable cellular composition and quality. More recently, however, chemically defined protocols that induce rapid and virtually complete neural conversion have been developed; these should ultimately lead to standardized strategies for driving differentiation of hPSCs to relevant neuronal cell types.

A major breakthrough was the development of protocols that robustly, reproducibly, and efficiently convert hPSCs into neural ectoderm tissue. Noggin, a bone morphogenetic protein inhibitor, had previously been demonstrated to have robust neural-inducing properties (Pera et al. [@CR86]). Similarly, the small molecule SB431542, which inhibits the Lefty/activin/transforming growth factor beta pathways by blocking phosphorylation of the ALK4, ALK5, and ALK7 receptors, enhances neural induction in hPSCs (Patani et al. [@CR81]). The combination of noggin and SB431542 (dual SMAD inhibition), then enabled rapid and uniform neural induction of hPSCs under adherent culture conditions, and allowed the derivation of relevant neuron subtypes in a shorter time (∼19 days) (Chambers et al. [@CR18]). Others have reported similarly efficient neural induction in both hESCs and hiPSCs with the small molecule dorsomorphin in place of noggin (Kim et al. [@CR54]). Although the dual SMAD inhibition protocol in its original form gives rise to a heterogeneous population of neuronal cell types (both telencephalic and diencephalic), recent modifications have enabled the derivation of more specialized neuronal precursor and mature neuron populations, including floor plate precursors, midbrain dopaminergic neurons, and cortical neurons (Fasano et al. [@CR35]; Kriks et al. [@CR60]; Shi et al. [@CR102]).

Accelerating differentiation towards homogeneous neuronal populations {#Sec13}
---------------------------------------------------------------------

HPSC-derived neurons presently require long maturation times to reach a level of neuronal connectivity that allows the study of synaptic physiology (60--120 days). In order to facilitate adaptation of these cultures for drug screening, future improvements will therefore have to focus on assessing synaptic physiology and accelerating neuronal maturation. For example, in several studies, electrophysiologically active human neurons initially exhibit immature properties, including smaller, slower action potentials and the inability to fire repetitively, in contrast to more mature neurons (Shi et al. [@CR102]). Thus, baseline intrinsic membrane properties (e.g., resting membrane potential, input resistance) and action potential firing properties (e.g., threshold, amplitude, rise time), as well as percentages of neurons with differing firing rates, define the degree of differentiation, and should be systematically monitored while optimizing neuronal protocols to model synaptic dysfunction.

Modeling neuronal circuitry deficits and properties of specific synapses, such as cortico-striatal and excitatory/inhibitory connections, requires cultures that are highly enriched for specific neuronal subpopulations. Fluorescence-activated cell sorting (FACS) has been used to isolate hiPSC-derived neural crest cells (Lee et al. [@CR62]), NPCs, and even mature neurons (Israel et al. [@CR52]; Yuan et al. [@CR119]). The use of specific combinations of neuronal cell surface markers may thus allow the prospective isolation of additional neuronal lineages. Significantly, in their study of hiPSC-derived neurons from patients with Alzheimer\'s disease, Goldstein and colleagues used FACS-based purification to reduce the variability in the efficiency of neuronal differentiation between hiPSC lines, providing increased power to identify disease-related changes (Israel et al. [@CR52]). The identification of additional cell surface neuronal markers of specific subtypes, particularly middle and upper layer cortical neurons and inhibitory neurons, will facilitate progress towards pure populations of specific cortical subpopulations. Although not explored in hPSCs to date, reporter constructs expressing green fluorescent protein, under the control of a lineage-specific promoter, may be generated by genome editing, allowing the enrichment of additional neuronal lineages, including those for which cell surface markers are not known.

Figure [2](#Fig2){ref-type="fig"} shows that using proliferating hPSC-derived NPCs as a starting point for differentiation dramatically shortens the time required to obtain mature neurons with gene expression profiles approximating that of human brain. Additional modulation of the composition of the differentiation factor cocktail can modestly accelerate maturation (Fig. [2](#Fig2){ref-type="fig"}). One exciting recent approach towards further speeding up differentiation and generating homogenous cell populations is direct lineage conversion from non-neuronal cells by the forced expression of neuronal transcription regulators (Pang et al. [@CR79]; Vierbuchen et al. [@CR113]). Overexpression of the forebrain transcription regulators ASCL1, BRN2, ZIC1, MYT1L, and OLIG2 directly converts human fibroblasts into neurons with forebrain glutamatergic properties within 21 days (Qiang et al. [@CR88]). However, fibroblasts have limited proliferative capacity in vitro, thus limiting the number of cells available from a patient biopsy. Dopaminergic neurons (Sanchez-Danes et al. [@CR90]) and motor neurons (Hester et al. [@CR48]) have been generated from hPSCs and NPCs by combining different sets of transcription factors, indicating that subtype-specific neuronal differentiation can be achieved. Such "induced neurons" from Alzheimer\'s and Parkinson\'s patients have shown disease-relevant cellular phenotypes (Qiang et al. [@CR88]; Sanchez-Danes et al. [@CR90],[@CR91]). Although this approach may help reduce some of the variability in cellular homogeneity associated with current morphogen-based procedures, it is clear that differentiation by forced transgene expression may not allow the observation of subtle defects in neuronal specification and maturation, such as those observed in TS neurons (Pasca et al. [@CR80]). Thus, although the usefulness of induced neurons in modeling the molecular and cellular defects of neurodegenerative diseases has been demonstrated, it remains to be seen whether they can also generate neurons capable of supporting a neuronal network relevant to neurodevelopmental disorders.Fig. 2Transcriptome analyses validate the relevance of hPSC-based models of neuronal differentiation. Principal component analysis (PCA) of the expression profiles of 4,818 genes of postmortem tissue samples from human cerebellum and frontal and temporal cortex (Voineagu et al. [@CR114]) are compared to the expression profiles of hESC-derived neural progenitor cells (NPCs) and their differentiated progeny (our unpublished work). NPCs were generated from hPSCs by dual SMAD inhibition and differentiated for 7--35 days (D) in medium containing BDNF, glial-derived neurotrophic factor, ascorbic acid and dibutyryl-cyclic adenosine monophosphate (+BGAA), or in basal medium (−BGAA). The analysis shows that transcriptomic profiles of neuronal cultures differentiated for 35 days more closely approximate that of human cortex than of cerebellum, suggesting cortical-like properties. Inclusion of BGAA increases the kinetics and/or extent of neuronal maturation

Cortical specification {#Sec14}
----------------------

Relatively simple differentiation protocols, such as the one used to generate the neurons analyzed in Fig. [2](#Fig2){ref-type="fig"}, can generate neurons that approximate the gene expression pattern of human cortex. However, these neurons do not recapitulate the elaborate cortical layer-specific specification seen in vivo. Particularly relevant to ASD disease modeling, inclusion of retinoic acid in the dual SMAD inhibition procedure leads to cortical neuron identity, based on the appearance of cortical projection markers in precursors, which subsequently give rise to upper and lower layer cortical projection neurons (Shi et al. [@CR102]). Remarkably, all classes of cortical projection neurons found in vivo are generated and the temporal order of their emergence recapitulates in vivo cortex development. Importantly, between 60 and 120 days after the onset of neuronal derivation, the retinoic acid/dual SMAD inhibition protocol yields mature cortical neurons with appropriate electrophysiological properties and functional synapses (Michaelson et al. [@CR74]; Shi et al. [@CR100],[@CR101]). Prolonged exposure to noggin resulted in robust induction of telencephalic/cortical genes, while shorter treatments yield a mixture of diencephalon and telencephalon induction, but the in vitro temporal sequence of generation of cortical neuron types again followed in vivo development. When cortical pyramidal neurons generated in vitro were transplanted into mouse neonatal brain, they developed axonal projections and dendritic morphology which corresponded to endogenous cortical neurons. Thus, the fact that neurons generated in vitro develop properties of human cortical neurons in vivo offers an unprecedented opportunity to study ASD both in vitro and in animal xenograft models. These recent studies bring hope that specific cortical neuronal circuitry can be modeled using hPSCs relevant to ASD. Given that the expanded upper layers of the cortex are a cardinal feature of the human cortex, the specific generation of these neurons from hPSCs has potential for revealing specific aspects of cortical circuitry dysfunction in ASD.

Neuronal circuits {#Sec15}
-----------------

MRI studies and postmortem analyses of autistic individuals have consistently demonstrated anatomical abnormalities in several brain regions (including cortical frontal lobe, striatum, amygdala, and cerebellum), while functional MRI studies found differences in the activity of specific brain areas during cognitive tasks when compared to neurotypical controls (Amaral et al. [@CR2]; Schumann and Nordahl [@CR95]). Thus, meaningful relationships will need to be established between the cellular, molecular, and network-based properties of hPSC-based models of ASD, on the one hand, and the anatomical and functional endophenotypes of ASD patients\' brains, on the other. In cellular models of ASD, disease-relevant dysfunction may reveal itself at distinct levels of functional complexity within the cell population (Fig. [3](#Fig3){ref-type="fig"}). The different phenotypic trajectories of different hPSC-based ASD models likely converge at several levels of functional complexity as well, illustrating the requirement for mature, synaptically connected neurons capable of sustaining a neuronal network (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Towards cellular models of neuronal network dysfunction. Shown here are the principal stages of differentiation of hPSCs towards synaptically competent mature neurons. **a** First, neural ectoderm induction generates characteristic three-dimensional rosette-like structures expressing the transcription factor PLZF and the tight-junction protein ZO1 (*upper*). From these, neuroepithelial precursors expressing NPC markers Sox2 and nestin can be isolated and expanded (*lower*). **b** Further differentiation yields neurons extending MAP2a/b-positive dendrites. **c** Maturing neurons show colocalized synaptic markers, such as the presynaptic marker synapsin and the postsynaptic density protein SHANK3. **d** Mature neuronal cultures form functionally connected neuronal networks, characterized by synchronized spontaneous network activity seen in recordings from multi electrode arrays. Pathways dysregulated in different forms of ASD may converge on the cellular and molecular levels, allowing identification of early phenotypes in neuronal cultures from patient-derived hiPSCs. Such phenotypes include the identification of translational and transcriptional dysfunction which at the cellular level may be associated with abnormal proliferation and differences in extent and kinetics of early neuronal differentiation. Other pathways may converge at the synapse level, requiring mature neurons with synaptic connections. Dysregulation at the neuronal connectivity level due to synaptic dysfunction may only be identified in human neuronal cultures forming relevant neuronal circuits that resemble those of the human cortex

Aberrant neuronal network activity is strongly implicated as directly underlying many forms of brain dysfunction, including ASD. In particular, disruptions in the balance between excitatory/inhibitory (E/I) inputs have been observed in both ASD patients and mouse models of the disorder, pointing towards neural circuit dysfunction as the convergence point of pathophysiological trajectories that originate from diverse etiologies (Penzes et al. [@CR85]). For example, *Cntnap2* knockout mice, lacking a gene associated with ASD, show reduced numbers of GABAergic interneurons and decreased neuronal synchrony in the cortex (Penagarikano et al. [@CR84]). Moreover, ASD mouse models engineered to display disinhibition of eIF4E-dependent control of protein synthesis have a decreased ratio between inhibitory and excitatory synaptic inputs (Gkogkas et al. [@CR43]; Santini et al. [@CR93]). Thus, the relevance of hPSC-based cellular models for ASD ultimately hinges on the successful in vitro generation of functional neuronal networks, characterized by synaptically connected excitatory and inhibitory neurons at physiologically relevant proportions. Given the different developmental origins and lineages of excitatory cortical pyramidal neurons and inhibitory interneurons, it remains a challenge to simultaneously produce both cell types in appropriate ratios from the same culture. Their separate generation by different protocols and subsequent coculture may provide a way forward. Indeed, protocols have recently been devised to direct the differentiation of hPSCs towards progenitors resembling those of the medial ganglionic eminence and further into forebrain interneurons (Nicholas et al. [@CR78]) .

In the brain, inhibitory interneurons play a critical role in maintaining neural synchrony of oscillatory activity in local circuits (Huang et al. [@CR51]). Since defects in synchrony are associated with neuropsychiatric disorders including ASD and schizophrenia (Penzes et al. [@CR85]), there has been much interest in establishing neuronal in vitro cultures capable of supporting such synchronous activity. In their study of hiPSC-derived neurons from patients with schizophrenia, Brennand et al. ([@CR13]) observed reduced neuronal connectivity and glutamate receptor expression but, surprisingly, no abnormal synapse-dependent synchronous activity. Thus, it may be ambitious to expect that we can replicate complex brain network oscillations in an in vitro system. Nevertheless, synchronization is a sensitive measure of the maturity and connectivity of such in vitro neuronal networks, and so this functional readout may help reveal defects in network properties that are too subtle to be detected by cellular assays. Synchronous network activity can be monitored by culturing neurons on MEAs (Fig. [3](#Fig3){ref-type="fig"}) or by measuring intracellular calcium transients using Ca^2+^-sensitive dyes applied to neuronal cultures. MEAs allow repeated measurements of differentiation cultures over time, allowing investigation of maturation kinetics. In contrast to electrophysiological approaches, calcium imaging is amenable to higher-throughput assay formats, allowing the development of drug screens using hPSC-based cellular models of ASD. When combined with subsequent immunocytochemistry, specific neuronal subtypes (such as excitatory vs. inhibitory neurons) or subnetworks of cells that show aberrations in their network behavior can be identified. Owing to these advantages, it is therefore likely that measurement of network properties by calcium imaging will be one of the key technologies in translational ASD research.

Outlook {#Sec16}
=======

The key to understanding the pathophysiology of ASD and the development of therapeutics is the development of robust disease-relevant cellular models. These efforts comprise (1) establishing hiPSCs from biopsy material of ASD patients with diverse genetic etiologies and from neurotypical control individuals, (2) genetic engineering of normal hPSCs to generate matched isogenic sets of lines with targeted ASD-relevant genetic defects, (3) the development of robust, efficient and relevant neuronal differentiation protocols, and (4) the definition of ASD-related cellular phenotypes upon which corresponding cellular assays can be built. The design of these models and assays will need to be continuously informed and guided by insights from mouse models and from genetic, molecular, and functional studies in the ASD population. Given the diverse genetic and clinical landscape of ASD patients, it is evident that a single cellular model will not recapitulate all aspects of ASD pathology from all ASD patients. Nevertheless, our increased appreciation that different pathophysiological trajectories may converge on a limited set of molecular pathways fuels the hope that a limited number of cellular models may address a majority of relevant phenotypes. Major inroads into all these areas have been built in the recent past: the time is now ripe for hPSCs models to be implemented in ASD discovery research.
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